曲美他嗪对稳定型心绞痛患者血清同型半胱氨酸及谷氨酰转肽酶含量的影响

Effects of trimetazidine on serum-homocysteine and serum-gamma-glutamyl transferase level in the cases of stable angina cordis

目的:探讨曲美他嗪对冠心病患者血清同型半胱氨酸及谷氨酰转肽酶含量的影响。方法:选择稳定型心绞痛患者80例,对照组患者进行常规冠心病药物治疗,治疗组在常规治疗基础上加服曲美他嗪6个月,于治疗前后分别测定血清同型半胱氨酸(Hcy)及γ-谷氨酰转肽酶(GGT)含量。结果:与治疗前相比,在治疗6个月后,所有参与研究的患者血Hcy、GGT水平均有显著下降。与对照组相比,加服曲美他嗪6个月的患者血Hcy、GGT下降更为显著(t=3.147,P<0.05)。结论:对于稳定型心绞痛患者,在常规治疗基础上加用曲美他嗪,能有效降低血清Hcy及GGT水平,改善患者预后。

AIM： To investigate the effect of trimetazidine on serum-homocysteine and serum-gamma-glutamyl transferase level in the cases of stable angina cordis. METHODS： A total of 80 cases of stable angina cordis patients were included into this study. Conventional drug therapy for coronary heart disease was used for all the patients. In the treatment group,the additional therapy of 6-month trimetazidine was used. Serum-homocysteine and serumgamma-glutamyl transferase levels were detected before and after treatment. RESULTS： Compared with data collected before treatment,serum-homocysteine and serum-gamma-glutamyl transferase levels in all the patients were significantly decreased after the 6-month therapy. However, more decreases were found in serum-homocysteine and serum-gamma-glutamyl transferase levels in the patients with additional 6-month trimetazidine as compared with the control group. CONCLUSION： Routine treatment plus trimetazidine can effectively reduce the serum-homocysteine and serum-gamma-glutamyl transferase levels and improve patients-outcomes for the patients with stable angina cordis.